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Edited by Beat ImhofAbstract Macrophage inﬁltration in obese adipose tissue
provokes local inﬂammation and insulin resistance. Evidence
has accumulated that activation of 11b-HSD1 in adipocytes is
critically involved in dysfunction of adipose tissue. However,
the potential role of 11b-HSD1 in macrophages still remains
unclear. We here demonstrate that a murine macrophage cell
line, J774.1 cells expressed 11b-HSD1 mRNA and reductase
activity, both of which were augmented by lipopolysaccharide
(LPS)-induced cell activation. Three kinds of pharmacological
inhibition of 11b-HSD1 in LPS-treated macrophages signiﬁ-
cantly suppressed the expression and secretion of interleukin
1b, tumor necrosis factor a or monocyte chemoattractant protein
1, thereby highlighting a novel role of 11b-HSD1 in pro-inﬂam-
matory properties of activated macrophages.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Functional abnormalities in adipose tissue have been impli-
cated in the central pathophysiology of the metabolic
syndrome [1]. Glucocorticoids regulate adipocyte diﬀerentia-
tion, function and distribution, and in excess, cause visceral
fat obesity and convergence of metabolic diseases [2]. TwoAbbreviations: 11b-HSD1, 11b-hydroxysteroid dehydrogenase type 1;
11b-HSD2, 11b-hydroxysteroid dehydrogenase type 2; LPS, lipopoly-
saccharide; TLR4, toll-like receptor 4; IL-1b, interleukin 1b; IL1R1,
interleukin 1 receptor type 1; TNF-a, tumor necrosis factor a; TNFR1,
tumor necrosis factor receptor type 1; MCP-1, monocyte chemoat-
tractant protein 1; CCR2, chemokine (C–C motif) receptor 2; GR,
glucocorticoid receptor; SVF, stromal-vascular fraction; inhibitor A,
3-(1-adamantyl)-5,6,7,8,9,10-hexahydro[1,2,4]triazolo[4,3-a]azocine tr-
iﬂuoroacetate salt; inhibitor B(BVT-3498), 2,4,6-trichloro-N-(5,5-di-
methyl-7-oxo-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)benzenesulfona-
mide; CBX, carbenoxolone; DEX, dexamethasone
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doi:10.1016/j.febslet.2006.11.032iso-enzymes of 11b-HSD, 11b-HSD1 and 11b-HSD2 catalyze
the interconversion between hormonally active cortisol and
inactive cortisone within cells. 11b-HSD1 is abundantly ex-
pressed in adipose tissue and liver [2,3] and reactivates cortisol
from cortisone (oxo-reductase) [4]. Previous reports have
demonstrated that 11b-HSD1 predominates in adipocytes
compared to 11b-HSD2 [2], which inactivates cortisol to
cortisone (dehydrogenase). Targeted overexpression of 11b-
HSD1 selectively in adipose tissue in mice exempliﬁed meta-
bolic derangements including visceral fat obesity, insulin resis-
tance, dyslipidemia and hypertension [5,6]. Conversely,
systemic 11b-HSD1 knockouts as well as adipose-speciﬁc
11b-HSD2 overexpressors are completely protected against
metabolic diseases under overnutrition [7–9]. These data sug-
gest that increased level of adipose 11b-HSD1 plays a crucial
role in dysfunction of adipose tissue and resultant metabolic
disorders.
On the other hand, recent studies have demonstrated that
inﬁltration of macrophages in obese adipose tissue provokes
local and systemic inﬂammation and insulin resistance
[10–12]. It has been shown that matured adipocytes abun-
dantly express 11b-HSD1 which is critically involved in dys-
function of adipose tissue [2,5]. However, the potential role
of 11b-HSD1 in macrophages remains largely unclear. In this
context, we explored the expression and regulation of 11b-
HSD1 in a murine reticular cell sarcoma-derived J774.1
macrophages [13]. To our knowledge, this is the ﬁrst to demon-
strate that 11b-HSD1 is critically involved in pro-inﬂamma-
tory properties of activated macrophages.2. Materials and methods
2.1. Reagents and chemicals
All reagents were of analytical grade unless otherwise indicated.
Carbenoxolone [4,14,15], a non-selective inhibitor for 11b-HSD1 and
11b-HSD2 was obtained from Sigma (St. Louis, MO, USA).
Recently-developed 11b-HSD1 selective inhibitors, 3-(1-adamantyl)-
5,6,7,8,9,10-hexahydro[1,2,4] triazolo [4,3-a] azocine triﬂuoroacetate
salt (WO03/065983, Merck Co., USA) (inhibitor A for short, unless
otherwise indicated) [16] and 2,4,6-trichloro-N-(5,5-dimethyl-7-
oxo-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl) benzenesulfonamide
(BVT-3498, Biovitrum, Sweden) (inhibitor B for short, unless other-
wise indicated) [17,18] were synthesized according to the patent infor-
mation.blished by Elsevier B.V. All rights reserved.
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Mouse reticulum cell sarcoma-derived J774.1 cells [13] were obtained
from Cell Resource Center for Biomedical Research Institute of Devel-
opment, Aging and Cancer, Tohoku University, Japan. Cells were cul-
tured in RPMI 1640 plus 10% heat-inactivated FBS at 37 C in 5%CO2.2.3. Quantitative real time PCR
Total RNA was extracted using Trizol Reagent (Invitrogen, USA)
and cDNA was synthesized using iScript cDNA Synthesis Kit
(Bio-Rad, USA) according to the manufacturer’s instruction. The
sequence of probes and primers are summarized in Table 1. Taqman
PCR was performed using ABI Prism 7700 Sequence Detection System
as instructed by the manufacture (Applied Biosystems, USA). Level of
mRNA was normalized to those of 18S mRNA.
2.4. 11b-HSD1 enzyme activity assay
11b-HSD1 primarily acts as a reductase and reactivates cortisol
from cortisone in viable cells. On the other hand, under some condi-
tions such as tissue homogenate or microsome fraction, 11b-HSD1
acts as a dehydrogenase and inactivate cortisone to cortisol [2]. 11b-
HSD1 reductase activity in intact cells was measured as reported [2].
Brieﬂy, cells were incubated for 24 h in serum-free RPMI 1640, adding
250 nM cortisone including tritium labeled tracer [1,2-3H]2 cortisone
for reductase activity and 250 nM cortisol with [1,2,6,7-3H]4 cortisol
for dehydrogenase activity. Cortisol and cortisone were extracted using
ethyl acetate, evaporated and resuspended in ethanol, separated by
thin-layer chromatography in chloroform:methanol (95:5) and quanti-
ﬁed by autoradiography.
To validate inhibitory potency of compounds against 11b-HSD1,
using FreeStyle 293 cells transiently transfected with human 11b-
HSD1, the enzyme activity assay was carried out with 20 mM
Tris–HCl, pH 7.0, 50 lM NADPH, 5 lg protein of microsomal frac-
tion, 300 nM 3H-cortison for 2 h. The reaction was stopped by 18b-
Glycyrrhetinic acid. The labeled cortisol product was captured by
mouse monoclonal anti-cortisol antibody, bound to SPA beads coated
with protein A, and quantiﬁed in a scintillation counter.
2.5. Measurement of IL-1b, TNF-a and MCP-1 concentrations in
cultured media
Interleukin 1b (IL-1b), tumor necrosis factor a (TNF-a) and mono-
cyte chemoattractant protein 1 (MCP-1) concentrations in J774.1 cellTable 1
Sequences of TaqMan primers and probes
Gene GenBank accession no. Probe (FAM-50 ﬁ 30-
Hsd11b1 NM008288 TCCGAGTTCAAGGCAG
Hsd11b2 NM008289 TCAAGCCTGGCTGCTC
Il1b NM008361 CATGGCACATTCTGTT
Tnf NM013693 CCCGACTACGTGCTCC
Ccl2 NM011333 CCCCACTCACCTGCTG
Il1r1 NM008362 CCTGACTTCAAGAATT
Tnfrsf1a NM011609 AGTGAGTGCGTCCCTT
Ccr2 NM009915 CTCTGTCACCTGCATG
Nr3c1 NM008173 CCTGCTATGCTTTGCT
Tlr4 NM021297 CATGCCTTGTCTTCAA
Forward primers are designated by f and reverse primers by r.
Abbreviations: FAM, 6-carboxyﬂuorescein; TAMRA, 6-carboxytetramethylrh
hydroxysteroid 11-beta dehydrogenase 2; l1b, interleukin 1 beta; Tnf, tumo
chemokine (C–C motif) ligand 2, Il1r1; interleukin 1 receptor, type I, Tnfrsf
Ccr2, chemokine (C–C motif) receptor 2; Nr3c1 (=glucocorcoid receptor, G
receptor 4.(1 · 106 cells/ml) cultured media were measured by enzyme-linked
immunosorbent assay (ELISA) kits according to the manufacturers
instructions (R&D Systems, USA).
2.6. Statistical analysis
Data are expressed as the means ± S.E.M. of triplicate experiments.
Data were analyzed using one-way analysis of variance (ANOVA),
followed by Student’s t-tests for each pair for multiple comparisons.
Diﬀerences were considered signiﬁcant if P < 0.05.3. Results
3.1. 11b-HSD1 mRNA level and reductase activity were
substantially increased in activated J774.1 macrophages
Lipopolysaccharide (LPS) is a potent ligand for toll-like
receptor (TLR) 4 and a representative activator of macro-
phages [19,20]. When J774.1 cells were treated with LPS
(100 ng/ml) for 24 h, mRNA level of IL-1b, TNF-a and
MCP-1 was markedly increased compared to control (approx-
imately 1500-fold, 3-fold, 220-fold, respectively, P < 0.01).
LPS (100 ng/ml, 24 h) also substantially augmented 11b-
HSD1 mRNA level in J774.1 macrophages (20-fold vs.
control. P < 0.01) (Fig. 1A). 11b-HSD1 reductase activity
was concomitantly augmented by LPS (100 ng/ml) compared
to LPS-free control (2.9 ± 1.2-fold vs. control. P < 0.05)
(Fig. 1B). Notably, 11b-HSD1 dehydrogenase activity was un-
der-detectable not only at the basal but with LPS treatment
(Fig. 1C).
3.2. Eﬀect of pharmacological inhibition of 11b-HSD1 on
inﬂammatory properties in J774.1 macrophages
To explore the potential role of 11b-HSD1 in cytokine
release from activated macrophages, we examined the eﬀect
of pharmacological inhibition of 11b-HSD1 on gene expres-
sion of LPS-treated J774.1 cells. In the present study, twoTAMRA) Primer (50 ﬁ 3 0)
CGAGACACTACC f CCAGGTCGGAGGAAGGTCTC
r CCAGCAATGTAGTGAGCAGAGG
CAAGACAG f TCCCTGGGGTATCAAGGTCAG
r CTCCCAGAGGTTCACATTAGTCAC
CAAAGAGAGCCTG f TCGCTCAGGGTCACAAAGAAA
r CCATCAGAGGCAAGGAGGAA
TCACCCA f TCTCTTCAAGGGACAAGGCTG
r ATAGCAAATCGGCTGACGGT
CTACTCATTCA f TTGGCTCAGCCAGATGCA
r CCAGCCTACTCATTGGGATCA
ACCTCATCGG f GCATGTGCAGTTAATATACC
r CAATTGTAGCCGTGAGGATG
GCAGCC f GCAGGGTTCTTTCTGAGAG
r GGCACAACTTCATACACTCC
GCCTGGTCT f ATGAGTAACTGTGTGATTGACAAGCA
r GCAGCAGTGTGTCATTCCAAGA
CCTGATCTGATT f ATCATACAGACAAGCAAGTGGAA
r AGGGTAGAGTCATTCTCTGCTC
TTGTTTCAA f CTTCAGTGGCTGGATTTATC
r GAGGTGGTGTAAGCCATG
odamine. Hsd11b1, hydroxysteroid 11-beta dehydrogenase 1; Hsd11b2,
r necrosis factor; Ccl2 (=monocyte chemoattractant protein:MCP-1);
1a (=TNFR1), tumor necrosis factor receptor superfamily member 1a;
R); nuclear receptor subfamily 3, group C, member 1; Tlr4, toll-like
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Fig. 1. 11b-HSD1 mRNA expression and reductase activity were induced by LPS in J774.1 macrophages. J774.1 cells (1 · 106 cells/ml, not-conﬂuent)
were treated with LPS (10–103 ng/ml, 12 or 24 h). (A) Level of mRNA for 11b-HSD1 was determined by real-time PCR. Level of each mRNA was
normalized to that of 18S rRNA. (B) (left): 11b-HSD1 reductase activity (expressed as conversion ability of cortisone to cortisol) and (right): 11b-
HSD1 dehydrogenase activity (expressed as conversion ability of cortisol to cortisone) were assessed in the media of J774.1 cells treated with 10 ng/ml
LPS for 24 h. Reference corresponds to [3H] cortisone or [3H] cortisol used as a size marker. A representative autoradiograph of thin-layer
chromatography (TLC) in 11b-HSD activity assay (upper) and quantiﬁcation ( lower). Intensities of signals at cortisol and cortisone correspond to
the enzyme activity of reductase and dehydrogenase, respectively. U.D.; under detectable. Data are expressed as mean ± S.E.M. of triplicate
experiments. *P < 0.05 vs. vehicle (V) treated group.
T. Ishii et al. / FEBS Letters 581 (2007) 349–354 351kinds of 11b-HSD1 selective inhibitors: inhibitor A and inhib-
itor B were synthesized and employed (as mentioned in mate-
rials and methods). 11b-HSD1 and 11b-HSD2 non-selective
inhibitor, carbenoxolone (CBX) was also utilized. Based on
our data that 11b-HSD2 mRNA (data not shown) and corre-
sponding enzyme activity (dehydrogenase) [2,3] were under
detectable in J774.1 cells even with LPS treatment (Fig. 1),
CBX was considered to act virtually as a speciﬁc inhibitor
against 11b-HSD1.
In the microsome fraction assay, we veriﬁed that inhibitor A
(100 lM), inhibitor B (100 lM) and CBX (1 lM), all potently
inhibited 11b-HSD1 activity as little as 25% vs. control, respec-
tively (Fig. 2A). In J774.1 cells, treatment of inhibitor A
(10 lM), inhibitor B (100 lM), and CBX (100 lM) markedly
inhibited 11b-HSD1 activity (48 ± 23% [P < 0.05], 30 ± 1%
[P < 0.01], and 80 ± 7% [P < 0.01] of reduction vs. LPS-treatedcells, respectively), conﬁrming that these compounds serve as
potent inhibitors against 11b-HSD1 in J774.1 cells (Fig. 2B).
Noteworthy is that treatment of J774.1 cells with inhibitor A
(10 lM), inhibitor B (100 lM) and CBX (100 lM) reduced IL-
1b mRNA level (27 ± 5%, 38 ± 10%, 88 ± 2% of reduction vs.
LPS-treated cells without compounds, respectively, P < 0.01)
(Fig. 3A, upper). Consequently, IL-1b concentration in the
media was markedly decreased (inhibitor A; 34 ± 10%, CBX;
75 ± 3% of reduction vs. LPS-treated cells, respectively,
P < 0.01) (Fig. 3A, lower). TNF-a mRNA (inhibitor B;
20 ± 11.7% [P < 0.05], CBX; 34 ± 5% [P < 0.01] of reduction
vs. LPS-treated cells, respectively) (Fig. 3B, upper) and its con-
centration in the media (inhibitor B: 41 ± 8%, CBX: 57 ± 4%
of reduction vs. LPS-treated cells, respectively, P < 0.01)
(Fig. 3B, lower) were also signiﬁcantly suppressed by the treat-
ment of 11b-HSD1 inhibitors. In MCP-1, only CBX exerted
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Fig. 2. 11b-HSD1 activity assay for validation of 11b-HSD1 inhibitors. (A) Microsome fraction 11b-HSD1 activity assay: inhibitor A (0.01–
100 lM), inhibitor B (0.1–100 lM), CBX, carbenoxolone (0.01–10 lM). The x-axis shows the log concentration of each inhibitor and the y-axis
shows log% inhibition of 11b-HSD1 activity compared to control. (B) Intact cell assay for 11b-HSD1 reductase activity. J774.1 cells were incubated
for 24 h in serum-free RPMI 1640, adding 250 nM of cortisone with tritium labeled cortisone (left): a representative autoradiograph of TLC in 11b-
HSD activity assay and (right): quantiﬁcation of 11b-HSD activities. Intensities of signals at cortisol correspond to the enzyme activity of reductase.
The y-axis shows the percentage of 11b-HSD1 reductase activity compared to LPS (10 mg/ml) treated cells per se. Treatment of inhibitor A (10 lM),
inhibitor B (100 lM), and CBX (100 lM) substantially reduced 11b-HSD1 activity in J774.1 cells (inhibitor A and inhibitor B as mentioned in
Section 2).
352 T. Ishii et al. / FEBS Letters 581 (2007) 349–354signiﬁcant eﬀect on the mRNA level (48 ± 11% of reduction vs.
LPS-treated cells. P < 0.01) (Fig. 3C, upper) and concentration
in the media (57 ± 4% of reduction vs. LPS-treated cells.
P < 0.01) (Fig. 3C, lower).
The mRNA level of IL1R1 (receptor for IL-1b), TNFR1
(receptor for TNF-a), CCR2 (receptor for MCP-1), toll-like
receptor 4 (TLR4) (receptor for LPS) and GR (receptor for
glucocorticoid) was not signiﬁcantly changed with these 11b-
HSD1 inhibitors (data not shown).
3.3. Eﬀect of dexamethasone on inﬂammatory properties in
J774.1 macrophages
We examined the eﬀect of glucocorticoid replenishment on
the secretion of pro-inﬂammatory cytokine and chemokine in
J774.1 macrophages. Treatment of J774.1 cells with dexameth-
asone (DEX) (1010–107 M, 24 h) suppressed the mRNA
expression and secretion of IL-1b, TNFa and MCP-1 in a
dose-dependent manner (supplementary ﬁgure A–F). Further-
more, co-treatment of LPS (10 ng/ml) with DEX markedly
reduced the expression and secretion of IL-1b, TNFa and
MCP-1 dose-dependently (supplementary ﬁgure A–F).
Treatment of J774.1 cells with DEX (107 M) reduced IL-1b
mRNA level (85 ± 8% of reduction vs. vehicle, 91 ± 0.1% of
reduction vs. LPS-treated cells, respectively, P < 0.01). Conse-quently, IL-1b concentration in the media was decreased
(83 ± 8% of reduction vs. LPS-treated cells, P < 0.01) (supple-
mentary ﬁgure A, D). Regarding TNF-a, mRNA (55 ± 8% of
reduction vs. vehicle, 47 ± 14% of reduction vs. LPS-treated
cells, respectively, P < 0.01) and concentration in the media
(51 ± 14% of reduction vs. vehicle, 43 ± 8% of reduction vs.
LPS-treated cells, respectively, P < 0.01) were markedly sup-
pressed by DEX (supplementary ﬁgure B, E). Regarding
MCP-1, DEX also decreased the mRNA level (65 ± 4% of
reduction vs. vehicle [P < 0.05], 83 ± 3% of reduction vs.
LPS-treated cells [P < 0.01], respectively) and concentration
in the media (81 ± 10% of reduction vs. vehicle, 68 ± 5% of
reduction vs. LPS-treated cells, respectively, P < 0.01) (supple-
mentary ﬁgure C, F).4. Discussion
Here, we demonstrated that J774.1 macrophages expressed
considerable amount of mRNA and reductase activity of
11b-HSD1. Our data is the ﬁrst to demonstrate that the cell
activation with LPS markedly augmented mRNA expression
and reductase activity of 11b-HSD1, accompanied by a drastic
morphological change and increased secretion of pro-inﬂam-
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Fig. 3. Pharmacological inhibition of 11b-HSD1 considerably reduced IL-1 b, TNF-a or MCP-1 expression in and secretion from LPS-activated
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activated J774.1 macrophages: J774.1 cells were activated by LPS (10 ng/ml) and co-treated with inhibitor A (10 lM), inhibitor B (100 lM) or CBX
(100 lM) for 24 h. (upper); mRNA for IL-1b, TNF-a and MCP-1 determined by real-time PCR. Level of each mRNA was normalized to that of 18S
rRNA and expressed as a relative value vs. control (lower). Concentrations of IL-1b, TNF-a and MCP-1 in the media measured by ELISA. Data are
expressed as means ± S.E.M. of triplicate experiments. **P < 0.01 vs. vehicle (V) treated group. #P < 0.05, ##P < 0.01 vs. LPS-treated cells.
T. Ishii et al. / FEBS Letters 581 (2007) 349–354 353matory cytokines [13]. Recent studies highlighted the concept
that not only LPS but non-microbial molecules such as
fatty acids can also activate macrophages through TLR4
[21]. It is also suggested that endogenous, intestine-derived
LPS contributes to the pathophysiology of obesity-associated
fatty liver diseases [22]. In this context, potential mechanism
of LPS-mediated dysfunction of adipose tissue stimulates
much interest in future studies.
Glucocorticoids are widely used as anti-inﬂammatory agents
in human clinics [23]. Consistent with the notion that glucocor-
ticoids act as anti-inﬂammatory hormones, our data demon-
strated that treatment of J774.1 cells with dexamethasone
signiﬁcantly suppressed the mRNA expression and secretion
of IL-1b, TNF-a and MCP-1 in a dose-dependent manner
(supplementary ﬁgure). On the other hand, physiological ef-
fects of endogenous glucocorticoids are distinct from those
in pharmacological or therapeutic concentrations of synthetic
cortisol analogues [24–27]. A recent study showed that 11b-
HSD1-mediated intracellular glucocorticoid reampliﬁcation
in macrophages enhanced phagocytic activity [28]. However,
it still remains controversial whether the activation of 11b-
HSD1 is involved in pro-inﬂammatory properties of macro-
phages. To test the possibility, we assessed the potential impact
of pharmacological inhibition of 11b-HSD1 on secretion of
pro-inﬂammatory cytokine and chemokine. Our data demon-
strated for the ﬁrst time that treatment of J774.1 cells with
three structurally distinct 11b-HSD1 inhibitors considerably
suppressed the mRNA expression and secretion of IL-1b,TNF-a or MCP-1, clearly indicating that intracellular regener-
ation of active glucocorticoid via 11b-HSD1 does exert
pro-inﬂammatory eﬀects on activated macrophages. Taking
structural and pharmacological diﬀerences of compounds into
consideration, further investigation is required to reinforce the
result.
Macrophages play pathophysiologic roles in adipose dys-
function, arteriosclerosis [16] and inﬂammatory fatty liver
diseases [22]. A recent study showed that pharmacologic inhi-
bition of 11b-HSD1 ameliorated diabetes, dyslipidemia [29]
and arteriosclerosis [16] in mouse models. It should also be
noted that, reminiscent of adipocytes [16]. 11b-HSD1 expres-
sion and reductase activity is predominated in macrophages
(Fig. 1), while that of 11b-HSD2 and dehydrogenase activity
were not detected in our assays (data not shown). Taken to-
gether, our results suggest that 11b-HSD1 in activated macro-
phages may be a novel target for the treatment of metabolic
diseases.
In adipose tissue, 11b-HSD1 was expressed not only in ma-
ture adipocytes but also stromal vascular fraction (SVF) cells
which include inﬁltrated macrophages [30]. Number of cells
contained in SVF was estimated to be two-thirds of that in
whole adipose tissue [31]. Our data in human adipose tissue
biopsies also showed that SVF from adipose tissue expressed
11b-HSD1 to a considerable extent (approximately 20% of
that in ﬂoating matured adipocytes) (Yasue, S. et al. manu-
script in preparation). Thus, 11b-HSD1 in activated macro-
phages may play a role in the pathophysiology of adipose
354 T. Ishii et al. / FEBS Letters 581 (2007) 349–354inﬂammation and dysfunction. Further investigations in vivo
should validate this notion and may open a fresh avenue for
molecular and cellular mechanism of adipose inﬂammation
and dysfunction.
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